| Forecasting individual progression trajectories in Huntington disease enables more powered clinical trials I Koval, T Dighiero-Brecht, AJ Tobin, SJ Tabrizi, RI Scahill, ... Scientific Reports 12 (1), 18928, 2022 | 7 | 2022 |
| Machine learning spots the time to treat Huntington disease I Koval, T Dighiero-Brecht, A Tobin, S Tabrizi, R Scahill, S Durrleman, ... | 2 | 2021 |
| MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1 M Flower, V Lomeikaite, M Ciosi, S Cumming, F Morales, K Lo, ... Brain 142 (7), 1876-1886, 2019 | 147 | 2019 |
| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 306 | 2017 |
| Cloned glutamic acid decarboxylase AJ Tobin, MG Erlander, DL Kaufman US Patent 8,926,966, 2015 | | 2015 |
| From Catalysis to Mass Action: The Evolution of CHDI Foundation, a Drug‐Development Organization Devoted to Huntington's Disease AJ Tobin Collaborative Innovation in Drug Discovery, 411-435, 2014 | 1 | 2014 |
| FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED AJ Tobin Collaborative Innovation in Drug Discovery: Strategies for Public and …, 2014 | | 2014 |
| 8OHdG is not a biomarker for Huntington disease state or progression B Borowsky, J Warner, BR Leavitt, SJ Tabrizi, RAC Roos, A Durr, ... Neurology 80 (21), 1934-1941, 2013 | 30 | 2013 |
| Q-motor–Quantitative motor assessments: Potential novel endpoints for clinical trials in pre-manifest and symptomatic Huntington's disease–36 months longitudinal results from … R Reilmann, S Bohlen, C Saß, C Jauffret, A Sturrock, A Coleman, J Read, ... Basal ganglia 3 (1), 67-68, 2013 | 9 | 2013 |
| F14 8OHdG is not a biomarker for Huntington's disease; lessons for future biomarker studies B Borowsky, J Warner, W Matson, H Johnson, A Durr, R Roos, SJ Tabrizi, ... Journal of Neurology, Neurosurgery & Psychiatry 83 (Suppl 1), A25-A26, 2012 | 2 | 2012 |
| From Catalysis to Mass Action: The Evolution of CHDI Foundation, a Drug-Development Organization Devoted to Huntington’s Disease Allan J. Tobin AJ Tobin | | 2011 |
| Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline LB Menalled, M Patry, N Ragland, PAS Lowden, J Goodman, J Minnich, ... PloS one 5 (3), e9793, 2010 | 79 | 2010 |
| Publisher version _ All articles available through Birkbeck ePrints are protected by intellectual property law, including copyright law LB Menalled, M Patry, N Ragland, PAS Lowden, J Goodman, J Minnich, ... | | 2010 |
| TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data SJ Tabrizi, DR Langbehn, BR Leavitt, RA Roos, A Durr, D Craufurd, ... Lancet Neurol 8 (9), 791-801, 2009 | 174 | 2009 |
| Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data SJ Tabrizi, DR Langbehn, BR Leavitt, RAC Roos, A Durr, D Craufurd, ... The Lancet Neurology 8 (9), 791-801, 2009 | 1049 | 2009 |
| Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models L Menalled, BF El-Khodor, M Patry, M Suárez-Fariñas, SJ Orenstein, ... Neurobiology of disease 35 (3), 319-336, 2009 | 370 | 2009 |
| Nucleic acid encoding GAD65 AJ Tobin, MG Erlander, DL Kaufman US Patent 7,329,511, 2008 | | 2008 |
| Use of c-fos to identify activity-dependent spinal neurons after stepping in intact adult rats SN Ahn, JJ Guu, AJ Tobin, VR Edgerton, NJK Tillakaratne Spinal Cord 44 (9), 547-559, 2006 | 57 | 2006 |
| Cloned glutamic acid decarboxylase A Tobin, M Erlander, D Kaufman US Patent App. 10/641,149, 2005 | 29 | 2005 |
| Asking about life AJ Tobin, J Dusheck (No Title), 2005 | 78 | 2005 |
